{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T17:26:17Z","timestamp":1795195577330,"version":"4.10.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T00:00:00Z","timestamp":1520294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1038\/s41375-018-0089-x","type":"journal-article","created":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T07:23:21Z","timestamp":1520321001000},"page":"1380-1392","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study"],"prefix":"10.1038","volume":"32","author":[{"given":"Reinhard","family":"Stauder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-2501","authenticated-orcid":false,"given":"Ge","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin A.","family":"Koinig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Bagguley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argiris","family":"Symeonidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2767-8191","authenticated-orcid":false,"given":"Guillermo","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslav","family":"Cermak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Mittelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hellstr\u00f6m-Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Langemeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Skov","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"M\u0105dry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Malcovati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelia","family":"Tatic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandar","family":"Savic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corine","family":"van Marrewijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Guerci-Bresler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Lu\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Droste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Efficace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"de Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,6]]},"reference":[{"key":"89_CR1","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1182\/blood-2013-03-492884","volume":"122","author":"L Malcovati","year":"2013","unstructured":"Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del Canizo C, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013;122:2943\u201364.","journal-title":"Blood"},{"key":"89_CR2","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079\u201388.","journal-title":"Blood"},{"key":"89_CR3","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454\u201365.","journal-title":"Blood"},{"key":"89_CR4","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","volume":"32","author":"H Wildiers","year":"2014","unstructured":"Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32:2595\u2013603.","journal-title":"J Clin Oncol"},{"key":"89_CR5","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/S1470-2045(16)30510-1","volume":"17","author":"A Bottomley","year":"2016","unstructured":"Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, et al. Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncol. 2016;17:e510\u20134.","journal-title":"Lancet Oncol"},{"key":"89_CR6","doi-asserted-by":"crossref","unstructured":"Patel SS, Gerds AT. Patient-reported outcomes in myelodysplastic syndromes and MDS\/MPN overlap syndromes: stepping onto the stage with changing times. Curr Hematol Malig Rep. 2017;12:455\u201360.","DOI":"10.1007\/s11899-017-0406-x"},{"key":"89_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.leukres.2007.10.015","volume":"32","author":"DP Steensma","year":"2008","unstructured":"Steensma DP, Heptinstall KV, Johnson VM, Novotny PJ, Sloan JA, Camoriano JK, et al. Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey. Leuk Res. 2008;32:691\u20138.","journal-title":"Leuk Res"},{"key":"89_CR8","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/bjh.13138","volume":"168","author":"F Efficace","year":"2015","unstructured":"Efficace F, Gaidano G, Breccia M, Criscuolo M, Cottone F, Caocci G, et al. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. Br J Haematol. 2015;168:361\u201370.","journal-title":"Br J Haematol"},{"key":"89_CR9","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(15)00206-5","volume":"16","author":"F Efficace","year":"2015","unstructured":"Efficace F, Gaidano G, Breccia M, Voso MT, Cottone F, Angelucci E, et al. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. Lancet Oncol. 2015;16:1506\u201314.","journal-title":"Lancet Oncol"},{"key":"89_CR10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3324\/haematol.2012.067892","volume":"98","author":"B Deschler","year":"2013","unstructured":"Deschler B, Ihorst G, Platzbecker U, Germing U, Marz E, de Figuerido M, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematol. 2013;98:208\u201316.","journal-title":"Haematol"},{"key":"89_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/bjh.14033","volume":"174","author":"R Buckstein","year":"2016","unstructured":"Buckstein R, Wells RA, Zhu N, Leitch HA, Nevill TJ, Yee KW, et al. Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study. Br J Haematol. 2016;174:88\u2013101.","journal-title":"Br J Haematol"},{"key":"89_CR12","doi-asserted-by":"publisher","unstructured":"Efficace F, Cottone F, Abel G, Niscola P, Gaidano G, Bonnetain F, et al. Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: an international study in patients with myelodysplastic syndromes. Cancer. https:\/\/doi.org\/10.1002\/cncr.3119 , 2017.","DOI":"10.1002\/cncr.3119"},{"key":"89_CR13","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.critrevonc.2015.07.012","volume":"96","author":"L Cannella","year":"2015","unstructured":"Cannella L, Caocci G, Jacobs M, Vignetti M, Mandelli F, Efficace F. Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned? Crit Rev Oncol Hematol. 2015;96:542\u201354.","journal-title":"Crit Rev Oncol Hematol"},{"key":"89_CR14","first-page":"3671","volume":"96","author":"BD Cheson","year":"2000","unstructured":"Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671\u20134.","journal-title":"Blood"},{"key":"89_CR15","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","volume":"1","author":"AC Dueck","year":"2015","unstructured":"Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, et al. Validity and reliability of the US National Cancer Institute\u2019s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol. 2015;1:1051\u20139.","journal-title":"JAMA Oncol"},{"key":"89_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1046\/j.1365-2141.2003.04272.x","volume":"121","author":"AJ Jansen","year":"2003","unstructured":"Jansen AJ, Essink-Bot ML, Beckers EA, Hop WC, Schipperus MR, Van Rhenen DJ. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol. 2003;121:270\u20134.","journal-title":"Br J Haematol"},{"key":"89_CR17","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1046\/j.1365-2141.2003.04153.x","volume":"120","author":"E Hellstrom-Lindberg","year":"2003","unstructured":"Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IMS, Dybedal I, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin plus granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120:1037\u201346.","journal-title":"Br J Haematol"},{"key":"89_CR18","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3324\/haematol.2015.140335","volume":"101","author":"GA Abel","year":"2016","unstructured":"Abel GA, Efficace F, Buckstein RJ, Tinsley S, Jurcic JG, Martins Y, et al. Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS). Haematol. 2016;101:781\u20138.","journal-title":"Haematol"},{"key":"89_CR19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jgo.2015.05.003","volume":"6","author":"KR Fega","year":"2015","unstructured":"Fega KR, Abel GA, Motyckova G, Sherman AE, DeAngelo DJ, Steensma DP, et al. Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults. J Geriatr Oncol. 2015;6:288\u201398.","journal-title":"J Geriatr Oncol"},{"key":"89_CR20","first-page":"136","volume":"2","author":"EN Oliva","year":"2012","unstructured":"Oliva EN, Finelli C, Santini V, Poloni A, Liso V, Cilloni D, et al. Quality of life and physicians\u2019 perception in myelodysplastic syndromes. Am J Blood Res. 2012;2:136\u201347.","journal-title":"Am J Blood Res"},{"key":"89_CR21","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/bjh.13450","volume":"170","author":"L Swart de","year":"2015","unstructured":"de Swart L, Smith A, Johnston TW, Haase D, Droste J, Fenaux P, et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol. 2015;170:372\u201383.","journal-title":"Br J Haematol"},{"key":"89_CR22","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53\u201372.","journal-title":"Health Policy"},{"key":"89_CR23","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s10198-003-0182-5","volume":"4","author":"W Greiner","year":"2003","unstructured":"Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ. 2003;4:222\u201331.","journal-title":"Eur J Health Econ"},{"key":"89_CR24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/09286580601139212","volume":"14","author":"M Langelaan","year":"2007","unstructured":"Langelaan M, de Boer MR, van Nispen RM, Wouters B, Moll AC, van Rens GH. Impact of visual impairment on quality of life: a comparison with quality of life in the general population and with other chronic conditions. Ophthalmic Epidemiol. 2007;14:119\u201326.","journal-title":"Ophthalmic Epidemiol"},{"key":"89_CR25","doi-asserted-by":"crossref","unstructured":"Szende A, Williams A. Measuring self-reported population health\u2014an International Perspective based on EQ-5D. EuroQol Group, 2012.","DOI":"10.1016\/j.jval.2013.08.812"},{"key":"89_CR26","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s11136-005-8028-5","volume":"14","author":"EI Lubetkin","year":"2005","unstructured":"Lubetkin EI, Jia H, Franks P, Gold MR. Relationship among sociodemographic factors, clinical conditions, and health-related quality of life: examining the EQ-5D in the U.S. general population. Qual Life Res. 2005;14:2187\u201396.","journal-title":"Qual Life Res"},{"key":"89_CR27","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407\u201315.","journal-title":"Control Clin Trials"},{"key":"89_CR28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.clinthera.2016.03.009","volume":"38","author":"AS Pickard","year":"2016","unstructured":"Pickard AS, Jiang R, Lin H-W, Rosenbloom S, Cella D. Using patient-reported outcomes to compare relative burden of cancer: EQ-5D and functional assessment of cancer therapy-general in eleven types of cancer. Clin Ther. 2016;38:769\u201377.","journal-title":"Clin Ther"},{"key":"89_CR29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1007\/s11899-016-0343-0","volume":"11","author":"ZA Frosch","year":"2016","unstructured":"Frosch ZA, Abel GA. Assessing quality of care for the myelodysplastic syndromes. Curr Hematol Malig Rep. 2016;11:402\u20137.","journal-title":"Curr Hematol Malig Rep"},{"key":"89_CR30","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40266-015-0312-7","volume":"32","author":"S Burgstaller","year":"2015","unstructured":"Burgstaller S, Wiesinger P, Stauder R. Myelodysplastic syndromes in the elderly: treatment options and personalized management. Drugs Aging. 2015;32:891\u2013905.","journal-title":"Drugs Aging"},{"key":"89_CR31","doi-asserted-by":"publisher","first-page":"4887","DOI":"10.1007\/s00520-016-3344-6","volume":"24","author":"F Efficace","year":"2016","unstructured":"Efficace F, Breccia M, Cottone F, Okumura I, Doro M, Riccardi F, et al. Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies. Support Care Cancer. 2016;24:4887\u201394.","journal-title":"Support Care Cancer"},{"key":"89_CR32","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/jnci\/djq097","volume":"102","author":"XS Wang","year":"2010","unstructured":"Wang XS, Cleeland CS, Mendoza TR, Yun YH, Wang Y, Okuyama T, et al. Impact of cultural and linguistic factors on symptom reporting by patients with cancer. J Natl Cancer Inst. 2010;102:732\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"89_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jgo.2011.10.001","volume":"3","author":"C Valentiny","year":"2012","unstructured":"Valentiny C, Kemmler G, Stauder R. Age, sex and gender impact multidimensional geriatric assessment in elderly cancer patients. J Geriatr Oncol. 2012;3:17\u201323.","journal-title":"J Geriatr Oncol"},{"key":"89_CR34","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00277-013-2001-0","volume":"93","author":"ME Hamaker","year":"2014","unstructured":"Hamaker ME, Mitrovic M, Stauder R. The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy. Ann Hematol. 2014;93:1031\u201340.","journal-title":"Ann Hematol"},{"key":"89_CR35","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1182\/blood-2013-11-540021","volume":"123","author":"GA Abel","year":"2014","unstructured":"Abel GA, Klaassen R, Lee SJ, Young NL, Cannella L, Steensma DP, et al. Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life. Blood. 2014;123:451\u20132.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0089-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0089-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-018-0089-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:33:53Z","timestamp":1684604033000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-018-0089-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["89"],"URL":"https:\/\/doi.org\/10.1038\/s41375-018-0089-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,6]]},"assertion":[{"value":"21 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was carried out within the EUMDS Registry which is supported by Novartis Oncology. T. de Witte is the project leader and C. van Marrewijk is the project manager of the EUMDS Registry. Outside the funding by Novartis Oncology, the following co-authors report grants or personal fees: R. Stauder received research funding and honoraria from Celgene, Teva and Novartis. T. de Witte reports grants from Celgene, personal fees from Incyte, personal fees from Amgen, personal fees from Incyte outside the submitted work. G. Sanz reports personal fees by Celgene. M. Mittelmann reports personal fees by Ofizer, Amgen, research grants by Celgene\/Neopharm, and advisory roles for Celgene, Amgen, and Janssen. A. Savic personal fees by Seattle Genetics, Novo Nordisk, and Amgen. F. Efficace reports personal fees by Bristol-Myers Squibb, Seattle Genetics, TEVA and Incyte; and research funding by Lundbeck, TEVA, and Amgen. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}